Cargando…
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
BACKGROUND: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. METHODS: We conducted a multicenter test-ne...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047210/ https://www.ncbi.nlm.nih.gov/pubmed/35438137 http://dx.doi.org/10.1093/cid/ciac292 |
_version_ | 1784695679012044800 |
---|---|
author | Maeda, Haruka Saito, Nobuo Igarashi, Ataru Ishida, Masayuki Suami, Kazuya Yagiuchi, Ai Kimura, Yuya Komino, Masaru Arai, Hiromi Morikawa, Toru Motohashi, Iori Miyazawa, Rei Moriyama, Tetsu Kamura, Hiroshi Terada, Mayumi Kuwamitsu, Osamu Hayakawa, Tomoichiro Sando, Eiichiro Ohara, Yasuji Teshigahara, Osamu Suzuki, Motoi Morimoto, Konosuke |
author_facet | Maeda, Haruka Saito, Nobuo Igarashi, Ataru Ishida, Masayuki Suami, Kazuya Yagiuchi, Ai Kimura, Yuya Komino, Masaru Arai, Hiromi Morikawa, Toru Motohashi, Iori Miyazawa, Rei Moriyama, Tetsu Kamura, Hiroshi Terada, Mayumi Kuwamitsu, Osamu Hayakawa, Tomoichiro Sando, Eiichiro Ohara, Yasuji Teshigahara, Osamu Suzuki, Motoi Morimoto, Konosuke |
author_sort | Maeda, Haruka |
collection | PubMed |
description | BACKGROUND: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. METHODS: We conducted a multicenter test-negative case-control study in patients aged ≥16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (≥90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16–64 years was also assessed. RESULTS: We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%–93.9%) among patients aged 16–64 years and 90.3% (95% CI, 73.6%–96.4%) among patients aged ≥65 years. Among patients aged 16–64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%–96.6%) within 1–3 months after full vaccination, and 86.4% (95% CI, 56.9%–95.7%) within 4–6 months. CONCLUSIONS: mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July–September 2021, when the Delta variant was dominant nationwide. |
format | Online Article Text |
id | pubmed-9047210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-90472102022-04-28 Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) Maeda, Haruka Saito, Nobuo Igarashi, Ataru Ishida, Masayuki Suami, Kazuya Yagiuchi, Ai Kimura, Yuya Komino, Masaru Arai, Hiromi Morikawa, Toru Motohashi, Iori Miyazawa, Rei Moriyama, Tetsu Kamura, Hiroshi Terada, Mayumi Kuwamitsu, Osamu Hayakawa, Tomoichiro Sando, Eiichiro Ohara, Yasuji Teshigahara, Osamu Suzuki, Motoi Morimoto, Konosuke Clin Infect Dis Major Article BACKGROUND: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. METHODS: We conducted a multicenter test-negative case-control study in patients aged ≥16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (≥90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16–64 years was also assessed. RESULTS: We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%–93.9%) among patients aged 16–64 years and 90.3% (95% CI, 73.6%–96.4%) among patients aged ≥65 years. Among patients aged 16–64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%–96.6%) within 1–3 months after full vaccination, and 86.4% (95% CI, 56.9%–95.7%) within 4–6 months. CONCLUSIONS: mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July–September 2021, when the Delta variant was dominant nationwide. Oxford University Press 2022-04-19 /pmc/articles/PMC9047210/ /pubmed/35438137 http://dx.doi.org/10.1093/cid/ciac292 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Maeda, Haruka Saito, Nobuo Igarashi, Ataru Ishida, Masayuki Suami, Kazuya Yagiuchi, Ai Kimura, Yuya Komino, Masaru Arai, Hiromi Morikawa, Toru Motohashi, Iori Miyazawa, Rei Moriyama, Tetsu Kamura, Hiroshi Terada, Mayumi Kuwamitsu, Osamu Hayakawa, Tomoichiro Sando, Eiichiro Ohara, Yasuji Teshigahara, Osamu Suzuki, Motoi Morimoto, Konosuke Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) |
title | Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) |
title_full | Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) |
title_fullStr | Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) |
title_full_unstemmed | Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) |
title_short | Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) |
title_sort | effectiveness of messenger rna coronavirus disease 2019 vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 infections during the delta variant epidemic in japan: vaccine effectiveness real-time surveillance for sars-cov-2 (versus) |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047210/ https://www.ncbi.nlm.nih.gov/pubmed/35438137 http://dx.doi.org/10.1093/cid/ciac292 |
work_keys_str_mv | AT maedaharuka effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT saitonobuo effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT igarashiataru effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT ishidamasayuki effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT suamikazuya effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT yagiuchiai effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT kimurayuya effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT kominomasaru effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT araihiromi effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT morikawatoru effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT motohashiiori effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT miyazawarei effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT moriyamatetsu effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT kamurahiroshi effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT teradamayumi effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT kuwamitsuosamu effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT hayakawatomoichiro effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT sandoeiichiro effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT oharayasuji effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT teshigaharaosamu effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT suzukimotoi effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus AT morimotokonosuke effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus |